Helix BioPharma Corp. (HBPCF)
OTCMKTS
· Delayed Price · Currency is USD
0.450
0.00 (0.00%)
Dec 23, 2024, 4:00 PM EST
Helix BioPharma Income Statement
Financials in millions CAD. Fiscal year is August - July.
Millions CAD. Fiscal year is Aug - Jul.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Oct '24 Oct 31, 2024 | Jul '24 Jul 31, 2024 | Jul '23 Jul 31, 2023 | Jul '22 Jul 31, 2022 | Jul '21 Jul 31, 2021 | Jul '20 Jul 31, 2020 | 2019 - 2015 |
| Selling, General & Admin | 3.23 | 3.26 | 1.05 | 1.5 | 3.25 | 2.75 | Upgrade
|
| Research & Development | 6.35 | 5.98 | 5.28 | 4.54 | 5.88 | 5.87 | Upgrade
|
| Operating Expenses | 9.58 | 9.24 | 6.33 | 6.04 | 9.13 | 8.62 | Upgrade
|
| Operating Income | -9.58 | -9.24 | -6.33 | -6.04 | -9.13 | -8.62 | Upgrade
|
| Interest Expense | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 | -0.03 | Upgrade
|
| Interest & Investment Income | 0.03 | 0.03 | 0.05 | 0 | - | 0.03 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.06 | -0.05 | -0 | -0.01 | 0.05 | 0.06 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.27 | - | - | 0 | -0.34 | - | Upgrade
|
| EBT Excluding Unusual Items | -9.35 | -9.26 | -6.3 | -6.06 | -9.43 | -8.56 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.01 | - | 0.01 | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | -0.5 | -0.14 | - | Upgrade
|
| Pretax Income | -9.35 | -9.26 | -6.29 | -6.56 | -9.57 | -8.56 | Upgrade
|
| Earnings From Continuing Operations | -9.35 | -9.26 | -6.29 | -6.56 | -9.57 | -8.56 | Upgrade
|
| Earnings From Discontinued Operations | - | - | - | - | 1.54 | -0.61 | Upgrade
|
| Net Income to Company | -9.35 | -9.26 | -6.29 | -6.56 | -8.04 | -9.17 | Upgrade
|
| Minority Interest in Earnings | - | - | - | - | - | 0.19 | Upgrade
|
| Net Income | -9.35 | -9.26 | -6.29 | -6.56 | -8.04 | -8.99 | Upgrade
|
| Net Income to Common | -9.35 | -9.26 | -6.29 | -6.56 | -8.04 | -8.99 | Upgrade
|
| Shares Outstanding (Basic) | 46 | 44 | 39 | 30 | 28 | 26 | Upgrade
|
| Shares Outstanding (Diluted) | 46 | 44 | 39 | 30 | 28 | 26 | Upgrade
|
| Shares Change (YoY) | 13.57% | 15.11% | 29.26% | 8.41% | 7.97% | 19.75% | Upgrade
|
| EPS (Basic) | -0.20 | -0.21 | -0.16 | -0.22 | -0.29 | -0.35 | Upgrade
|
| EPS (Diluted) | -0.20 | -0.21 | -0.16 | -0.22 | -0.29 | -0.35 | Upgrade
|
| Free Cash Flow | -4.23 | -5.23 | -5.54 | -6.51 | -9.3 | -10.84 | Upgrade
|
| Free Cash Flow Per Share | -0.09 | -0.12 | -0.14 | -0.22 | -0.34 | -0.42 | Upgrade
|
| EBITDA | -9.57 | -9.23 | -6.31 | -6.03 | -9.07 | -8.56 | Upgrade
|
| D&A For EBITDA | 0.01 | 0.01 | 0.01 | 0.01 | 0.06 | 0.06 | Upgrade
|
| EBIT | -9.58 | -9.24 | -6.33 | -6.04 | -9.13 | -8.62 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.